Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358528 | 0.92 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL3215335 | 0.92 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL367317 | 0.91 | PIK3CD (0.60) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL356115 | 0.91 | PIK3CD (0.60) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL13112862 | 0.90 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL355566 | 0.89 | PIK3CD (0.67) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL733723 | 0.89 | PIK3CD (0.56) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL357568 | 0.89 | PIK3CD (0.59) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL13112856 | 0.89 | PIK3CD (0.61) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 | |
| SCHEMBL356497 | 0.85 | PIK3CG (0.70) | PIK3CDPIK3CBPIK3CGPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2612862-A2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-10 | — | — | EP | claimed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | claimed |
| EP-1761540-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2007-03-14 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | claimed |
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | disclosed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CD 6/4885PIK3CB 14/4885PIK3CG 13/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CD 25/4885PIK3CB 37/4885PIK3CG 57/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CB 5/4885PIK3CG 4/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CB 5/4885PIK3CG 4/4885 |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885PIK3CB 3/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.